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background: Rhythm control with antiarrhythmic drugs (AADs) has failed to be superior to rate control in patients with heart failure (HF) 
and atrial fibrillation (AF). Although AF ablation with pulmonary vein isolation (PVI) may avoid the higher risks of AADs, success rates with 
PVI are likely lower in this population. We performed a meta-analysis of randomized controlled trials (RCTs) comparing PVI to rate control 
in patients with HF and AF.
Methods:  We searched Pubmed, Medline, Embase and Cochrane for prospective RCTs that compared rate control versus PVI in 
HF patients with AF. Trials that included patients with left ventricular ejection fraction (LVEF) <50% randomized to either a rate control 
strategy or PVI and that reported at least one of the studied outcomes were included. Study quality was assessed using the Jadad score. 
Heterogeneity of the studies was analyzed by Cochran’s Q statistics. Mantel Haenszel relative risk and mean difference were calculated 
using the fixed effect model.
results:  Four randomized control trials met our inclusion criteria and included 224 patients, all but 39 of which had persistent AF. PVI 
compared to rate control was associated with an 8.49% increase in LVEF at 6 to 12 months (mean difference 8.49; 95% CI 6.37; 10.61; 
P<0.001). PVI was superior to rate control strategy in improving quality of life with a significant decrease in Minnesota Living with Heart 
Failure (MLWHF) questionnaire scores (mean difference -11.68; 95% CI -16.68;-6.69; P<0.001). Peak oxygen consumption significantly 
increased in PVI compared to rate control patients (mean difference 3.16; 95% CI 1.09; 5.23; P=0.003). Results were similar including only 
trials enrolling subjects with persistent AF. There was no evidence of heterogeneity or publication bias among the reported outcomes.
Conclusion:  PVI of patients with HF and AF is superior to rate control in improving LVEF and quality of life. Prior to relegating HF patients 
with persistent or drug refractory AF to a rate control strategy, consideration should be given to performing PVI.
